Aerie Pharmaceuticals Inc. – as well as its share price – returned to its previous heights following positive results from the second phase III trial of its triple-action eye drop Rhopressa, which hit its endpoints in lowering intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.